Evidence map›Paper›PMID 38252039›Full record

SynthesisCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2024

Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis.

Nikita Sandeep Wagle, Sulki Park, David Washburn, Robert Ohsfeldt, Hye-Chung Kum, Amit G Singal

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nikita Sandeep WaglePopulation Informatics Lab, Texas A&M University, College Station, Texas.ORCID 0000-0003-1337-483X
Sulki ParkDepartment of Health Policy and Management, School of Public Health, Texas A&M, Health Science Center, College Station, Texas.ORCID 0000-0002-3167-1478
David WashburnPopulation Informatics Lab, Texas A&M University, College Station, Texas.ORCID 0000-0002-8820-8687
Robert OhsfeldtPopulation Informatics Lab, Texas A&M University, College Station, Texas.ORCID 0000-0002-6117-056X
Hye-Chung Kum *Population Informatics Lab, Texas A&M University, College Station, Texas.ORCID 0000-0002-6882-8053
Amit G Singal *Division of Digestive and Liver Diseases, UT Southwestern Medical Center, Dallas, Texas.ORCID 0000-0002-1172-3971

Funding

Multilevel factors for racial/ethnic and socioeconomic disparities in prognosis of hepatocellular carcinomaR01MD012565 · NIMHD · UT SOUTHWESTERN MEDICAL CENTER · PI SINGAL, AMIT, YOPP, ADAM · 2018 to 2022
$4.3M
Multi-level Evaluation of Racial/ethnic Disparities in Liver Disease OutcomesR01CA256977 · NCI · BAYLOR COLLEGE OF MEDICINE · PI KANWAL, FASIHA, SINGAL, AMIT · 2021 to 2025
$3.0M
NCI NIH HHS R01 CA256977NIMHD NIH HHS R01 MD012565
6 · The paper itself

Abstract

backgroundRacial and ethnic disparities in hepatocellular carcinoma (HCC) prognosis exist, partly related to differential failures along the cancer care continuum. We characterized racial and ethnic disparities in treatment receipt among patients with HCC in the United States.

methodsWe searched Medline, Embase, and CINAHL databases to identify studies published between January 2012 and March 2022 reporting HCC treatment receipt among adult patients with HCC, stratified by race or ethnicity. We calculated pooled odds ratios for HCC treatment using random effects models.

resultsWe identified 15 studies with 320,686 patients (65.8% White, 13.9% Black, 10.4% Asian, and 8.5% Hispanic). Overall, 33.2% of HCC patients underwent any treatment, and 22.7% underwent curative treatment. Compared with White patients, Black patients had lower odds of any treatment (OR 0.67, 95% CI 0.55-0.81) and curative treatment (OR 0.74, 95% CI 0.71-0.78). Similarly, Hispanic patients had lower pooled odds of curative treatment (OR 0.79, 95% CI 0.73-0.84).

conclusionsThere were significant racial and ethnic disparities in HCC treatment receipt, with Black patients having lower odds of receiving any and curative treatment while Hispanic patients having lower odds of curative treatment. IMPACT: Racial and ethnic differences in treatment receipt serve as an intervention target to reduce disparities in HCC prognosis.

Indexed as

Carcinoma, HepatocellularHealthcare DisparitiesLiver NeoplasmsEthnicityHumansRacial GroupsUnited States

Identifiers

PMID38252039
PMCPMC10990826

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.